b'Biomedical and Life Sciences100 College StreetFull Send Productions/Market New HavenAnchored by scientific research at Yale, theValisure launched the first ever online Analytical regions bioscience cluster includes both largePharmacy that dispenses chemically batch-pharmaceutical companies and small startups,validated medications direct to consumers. They developing new drugs, therapies and medicaluse laser-based technology to analyze the chemical devices. These businesses often tend to feedproperties and ingredients of every batch of from the research and innovation ties with higherprescription medication, over-the-counter drug and learning institutions, chemical manufacturing (e.g.supplement, and it dispenses without adding costs pharmaceuticals) and healthcare (medical research).to consumers.With a statewide priority focus on biosciences, theArvinas had a huge year with its initial public South Central Connecticut region is ground zerooffering ($120 million) and completing $55 million for biosciences infrastructure of skilled scientists,Series C financing to advance protein degradation technicians, lab space, plus a supplier network forplatform.everything from rubber gloves to medical-waste disposal. The region has established a reputationBiohaven received authorization to proceed for meticulous and marketable research throughfrom FDA and doses first subject with BHV-3500, companies like Arvinas, Biohaven Pharmaceuticals,a highly soluble small molecule CGRP receptor and Sema4. antagonist.RECENT MILESTONES ReNetX Bio, Inc. closed on its Series A Kleo Pharmaceuticals, a spin out of Yale,funding. The company plans to begin clinical trials has raised $21 million to support immunotherapyon its drug within the year.pipeline and are anticipating human trials by 2020. 60'